RecruitingPhase 2NCT06558214

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Studying Embryonal tumor of neuroepithelial tissue

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Florida
Principal Investigator
Ashley Ghiaseddin, MD
University of Florida
Intervention
Pembrolizumab(drug)
Enrollment
20 target
Eligibility
18-90 years · All sexes
Timeline
20242029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06558214 on ClinicalTrials.gov

Other trials for Embryonal tumor of neuroepithelial tissue

Additional recruiting or active studies for the same condition.

See all trials for Embryonal tumor of neuroepithelial tissue

← Back to all trials